The acquired immune deficiency syndrome (AIDS) pandemic was first recognized in 1981 in Los Angeles, California.[@ref1] Unfortunately, human immunodeficiency virus (HIV) infection was widespread throughout the world by the time these sentinel events were recognized. The HIV/AIDS pandemic has quickly advanced to become one of the great plagues of all time, now affecting between 30.6 and 36.1 million persons worldwide, including approximately 2.5 million Indians \[[Figure 1](#F1){ref-type="fig"}\].[@ref2],[@ref3] More than 2.08 million persons die of HIV/AIDS per year, worldwide.[@ref3] The pandemic has had pervasive effects on culture, economics, and policy, and has led to ″the single greatest reversal in human development″ in recent times.[@ref4] The aim of the present article is to provide a review of the medical management of HIV infection.

Four treatment strategies have been shown to prolong survival of patients with HIV/AIDS: antiretroviral therapy, prophylaxis for *Pneumocystis carinii*,[@ref5] prophylaxis for *Mycobacterium avium*[@ref6] and care by a physician experienced in the management of HIV/AIDS.[@ref7] Of these, only combination antiretroviral therapy, commonly called highly active antiretroviral therapy (HAART), frequently succeeds at reversing the otherwise inexorable progression of immunodeficiency, whereas *P. carinii* and *M. avium* prophylaxis prolong survival in a state of advanced immunodeficiency, during which time patients unfortunately are at increasing risk of advanced opportunistic complications of AIDS such as cytomegalovirus (CMV) retinitis.[@ref8] The current plan for widespread introduction of inexpensive co-trimoxazole prophylaxis[@ref9] will be of great value in improving survival, but the risk of CMV retinitis is likely to increase substantially as a result, in regions where HAART does not become widely used.

Highly active antiretroviral therapy is defined as ″an antiretroviral regimen that can reasonably be expected to reduce the viral load \<50 copies/mL in treatment-naïve patients″.[@ref10] A foundational advance leading to HAART was the recognition that combination antiretroviral therapy would be needed to prevent the development of viral resistance to antiretroviral agents. The HIV, an RNA virus, mutates approximately once per replication, as a result of the poor fidelity of its reverse transcriptase.[@ref11] This property enables HIV to rapidly develop resistance to antiretroviral treatments, unless the treatment succeeds at arresting replication nearly completely.[@ref12] Simultaneous use of multiple agents, usually three or more, attacking different aspects of HIV replication is successful because HIV would have to develop mutations simultaneously to all agents in use in order to escape control, an improbable event. However, scrupulous adherence to such therapy is extremely important for patients with HIV disease, because intermittent use of antiretroviral agents leads to the development of resistance.[@ref13] Less than 95% adherence is associated with a 3.5-fold higher risk of treatment failure.[@ref14]

The four classes of antiretroviral agents currently available are listed in [Table 1](#T1){ref-type="table"}. At present, available antiretroviral drugs have their effect by interfering with one of two HIV-encoded enzymes required for reproduction of the virus (reverse transcriptase, which transcribes HIV′s RNA genome; or HIV protease, which is involved in the assembly and release of daughter viral particles) or by inhibiting fusion of the viral particle with the target cell.

Inhibitors of reverse transcriptase are divided into two classes: nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs), which competitively inhibit the enzyme; and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which covalently inactivate the reverse transcriptase, exerting a highly potent effect. Nucleoside inhibitors were the first effective antiretroviral drugs to be developed, beginning with zidovudine (AZT) in 1987.[@ref15] When given as monotherapy, most of these drugs reduce the HIV load in peripheral blood on the order of 0.5 to 1.0 log~10~ units, followed by the rapid development of drug resistance. The six agents in this class \[[Table 1](#T1){ref-type="table"}\] are quite useful as a component of antiretroviral combination therapies, and are widely used. Being older medications, some of them are less expensive than newer antiretroviral agents. Tenofovir is a nucleotide, rather than a nucleoside reverse transcriptase inhibitor, which circumvents a common mechanism of NRTI resistance, but otherwise works in a similar fashion to its cousins.

Non-nucleoside reverse transcriptase inhibitors are more potent than nucleoside reverse transcriptase inhibitors because they covalently inactivate reverse transcriptase. Their side- effect profile has made the three agents in this class among the most popular agents for management of HIV infection, although costs tend to limit their use worldwide. Nevertheless, they are prone to extremely rapid development of resistance if not used in appropriate combinations with a high degree of adherence to the medication schedule.

Protease inhibitors make up a third class of antiretroviral agents, the first class of ″highly potent″ drugs to become available, suppressing HIV load by 1.0 to 2.0 log~10~ units when given as monotherapy. The HIV protease cleaves polyproteins generated by HIV-encoded mRNA; its blockade renders several essential viral enzymes inactive, resulting in production of defective HIV virions that are rapidly cleared.[@ref16],[@ref17] Nine such agents currently exist \[[Table 1](#T1){ref-type="table"}\]. Ideally, most are given in conjunction with ritonavir, for its ″boosting″ effect, which improves the pharmacokinetic profile of other protease inhibitors without incurring the extent of side-effects associated with full-dose ritonavir. Combination therapy with protease inhibitors and thymidine analog NRTIs, a highly effective antiretroviral combination, unfortunately is associated with metabolic disturbances and peripheral lipoatropy, which appear to be less common when protease inhibitors are combined with abacavir or tenofovir.[@ref18] The latter agents are more expensive than older NRTIs.

Enfuvirtide - the first agent in a fourth class of agents, fusion inhibitors, is a 36 amino acid peptide which inhibits the function of gp41, potently inhibiting the HIV-cellular membrane fusion sequence.[@ref19] Enfuvirtide is primarily used in wealthy countries as a salvage therapy, due to its great expense and the requirement that it be given by injection.

The arrival of HAART has led to one of the most spectacular reversals in modern medicine, converting what is otherwise an inexorably progressive, fatal disease into a chronic disease with a fairly good prognosis for those who receive HAART and benefit from it. Use of HAART results in a much reduced risk of mortality,[@ref20] reduced opportunistic infection risk,[@ref21] and improved quality of life,[@ref22] often with recovery to near-normal health. Epidemiologically, widespread use of HAART tends to result in increased prevalence of HIV/AIDS, because survival improves to a greater extent than decline in transmission of HIV infection.

Ocular complications of AIDS and their association with a patient′s current immune status, as given by the CD4 + T cell count, are summarized in [Table 2](#T2){ref-type="table"}. The risk of developing CMV retinitis has declined substantially among patients receiving HAART.[@ref23] Among patients already afflicted by CMV retinitis, use of HAART is associated with an 81% lower risk of mortality,[@ref24] a 46% lower risk of developing retinitis in previously unaffected second eyes,[@ref25] a 60% reduction in the risk of retinal detachment[@ref26] and an approximate 75% reduction in the risk of loss of visual acuity.[@ref27] Most patients who develop immune reconstitution characterized by a rise in the CD4+ T cell count to a level greater than 100 to 150 cells/µL for four to six months can safely stop anti-CMV therapy,[@ref28] with only rare exceptions.[@ref29] Some patients also develop immune recovery uveitis (the first immune recovery inflammatory syndrome described) in which recovery of anti-CMV immunity leads to intraocular inflammation - often a vitritis - sometimes causing vision loss.[@ref30]

Because the overall effects of immune recovery are overwhelmingly beneficial, use of HAART is the single most important intervention for patients with ocular complications of AIDS. In fact, even if substantial immune recovery never occurs, outcomes of CMV retinitis are substantially improved in patients receiving HAART with respect to those who never take HAART.[@ref24]-[@ref27] However, specific ocular therapy also is critical, in order to avoid blindness in the early months before immune recovery is complete, or if antiretroviral treatment fails to restore immunity.

Unfortunately, most persons with HIV/AIDS worldwide have limited access to HAART, as a result of both economic and health infrastructure limitations. In recent years, international efforts and cost reductions, largely because of generic drugs available from Indian pharmaceutical firms, have begun improving access to HAART. Still, only 1-1.5% of patients in India receive HAART presently, and the present goal is to expand to 6-7%.[@ref31] While it is encouraging to observe increasing use of combination antitretroviral therapy worldwide, it likely will be many years until treatment is available to the majority.

In the pre-HAART era, CMV retinitis was more than 20-fold more common than any other vision-threatening ocular complication of AIDS in the United States[@ref32] and affected approximately 30% of all patients with AIDS at some point in their lifetime.[@ref33] Case series from India and most parts of the world[@ref32]-[@ref42] suggest that CMV retinitis is the preeminent ocular complication of AIDS everywhere, except possibly in sub- Saharan Africa, where patients until recently have died at a stage of AIDS earlier than when CMV retinitis would be expected to occur,[@ref43] a situation which is likely to change with improved AIDS care and infrastructure. Even if the risk of CMV retinitis is one-fourth as common worldwide as it used to be in the United States, millions of persons would be affected.

Treatment of ocular complications of AIDS is a complex topic, which I have addressed in more detail elsewhere.[@ref44] In general, because most ocular opportunistic pathogens cannot be eradicated, their management, including the management of CMV retinitis, requires lifelong suppressive therapy except in those fortunate few in whom HAART induces sufficient recovery of endogenous immunity to control the pathogen. Management of CMV retinitis, the most common pathogen, is particularly difficult. Even with ongoing suppressive systemic anti-CMV therapy, recurrences of active retinitis occur approximately every three months,[@ref44] due to limitations in drug delivery after restoration of the blood-retinal barrier with healing of retinitis[@ref45] and/or the development of drug resistance, which occurs in about 27.5% by nine months.[@ref46] The alternative of local therapy is effective, but also has its problems, with increased risk of second eye retinitis,[@ref47] systemic CMV disease[@ref47] and possibly mortality[@ref24],[@ref47]-[@ref50] hence the overarching need in these patients to control the underlying HIV disease and restore endogenous immunity.

In countries with substantial treatment resources, valganciclovir[@ref51] is the most popular treatment for CMV retinitis, using a dose of 900 mg twice daily for initial control of active retinitis (″induction″), followed by 900 mg daily as suppressive (″maintenance″) therapy. Valganciclovir is the only oral treatment for CMV with high bioavailability, avoiding the need for a long-term central venous catheter, with its attendant high risk of life-threatening catheter complications[@ref52] and quality of life problems. Valganciclovir, the valine ester of ganciclovir, achieves blood ganciclovir levels similar to those with intravenous ganciclovir[@ref53]-[@ref55] and therefore can serve as a replacement for intravenous ganciclovir in most situations. Oral ganciclovir is inferior to valganciclovir because of poor oral bioavailability, and is no longer marketed in the west. Intravenous foscarnet[@ref55],[@ref56] is an alternative therapy for CMV disease, but requires several hours per day to administer, has significant side-effects, and is comparably expensive, making it a second-line therapy. Intravenous cidofovir is similarly effective,[@ref57],[@ref58] has become unpopular due to a high risk of substantial renal injury and uveitis/hypotony.[@ref59] Local therapy with ganciclovir implants is the most effective anti-CMV treatment option in terms of time-to-retinitis relapse, and is still used in wealthy countries for immediately vision-threatening disease,[@ref47],[@ref49],[@ref60],[@ref61] generally in combination with valganciclovir to prevent systemic complications (see above). However, because of the need to treat with valganciclovir anyway, most use valganciclovir monotherapy to treat lesions that are not immediately vision-threatening, particularly if there is hope for immune recovery. Intravitreal injections of fomivirsen[@ref62],[@ref63] are no longer marketed because demand for the product was poor.

As the cost of all of these regimens is exceptionally high, on an order substantially higher than first-line HAART, none of them are commonly used except in wealthy countries. The most common approach to treating CMV retinitis in a large part of the world is to use intravitreal injections of ganciclovir (2.0 to −5.0 mg/0.1 cc twice weekly for three weeks, then weekly) or occasionally foscarnet (2.4 mg/0.1 cc twice weekly for three weeks, then weekly). This approach, although it has not been subjected to randomized trials, seems effective based on case series[@ref64]-[@ref67] and clinical experience, but may be associated with a higher risk of second eye and systemic disease sequelae of CMV disease than a systemic treatment would be. Valganciclovir, which will not be available in generic form until 2014, may represent an improvement, particularly vis- à-vis systemic and second eye disease outcomes, but its cost- effectiveness as a generic drug vis-à-vis intravitreal injections remains to be seen.

With the anticipated widespread uptake of co-trimoxazole prophylaxis and absent full-scale implementation of HAART in most parts of the world, the number of cases of CMV retinitis, which may be already in the millions, is likely to nearly double. This substantial and increasing burden of disease calls for a more effective yet practical management strategy for CMV retinitis that can be implemented in resource-constrained settings. Ophthalmologists worldwide should be familiar with the diagnosis and management of CMV retinitis, and should establish partnerships with infectious diseases′ physicians able to provide appropriate treatment for patients with ocular complications of HIV/AIDS, because antiretroviral therapy is ultimately the most effective long-term treatment for CMV retinitis and for other ocular complications of AIDS. Research is needed to determine the optimal way of managing CMV retinitis in resource-constrained settings, particularly in the window before HAART-induced immune recovery occurs, during which the risk of vision loss and other complications is substantial.
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